<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467971</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200763_004</org_study_id>
    <nct_id>NCT03467971</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 2x2 Crossover Trial to Evaluate the Food Effect on the Bioavailability of a Metformin/Gliclazide Fixed Combination Tablet (1000 mg /30 mg MR) Given in Fasting and Fed Conditions to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the food effect on bioavailability of Metformin/Gliclazide fixed dose
      combination tablet in fed and fasted state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Actual">April 22, 2018</completion_date>
  <primary_completion_date type="Actual">April 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin/Gliclazide in Fasted State and With Food</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin/Gliclazide in Fasted State and With Food</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Metformin/Gliclazide in Fasted State and With Food</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Metformin/Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Time (t1/2) of Metformin/Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/f) of Metformin/Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/f) of Metformin/Gliclazide From Plasma</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin and Gliclazide fixed combination tablet in fasting state (Treatment period 1) followed by Metformin and Gliclazide fixed combination tablet in fed state (Treatment period 2). Each treatment period will be separated by a 14-day wash-out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin and Gliclazide fixed combination tablet in fed state (Treatment period 1) followed by Metformin and Gliclazide fixed combination tablet in fasting state (Treatment period 2). Each treatment period will be separated by a 14-day wash-out period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin/Gliclazide Fixed Combination</intervention_name>
    <description>Participants will receive single oral dose of Metformin and Gliclazide fixed combination tablet in fasting or fed state.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ethnicity: Mexicans

          -  Weight between 55 and 95 kilogram (kg)

          -  Body mass index between 18 and 27 kilogram per meter square (kg/m^2)

          -  Nonsmokers or participants who do not smoke more than 5 cigarettes or 1 pipe a day

          -  Good physical and mental health based on the clinical history and physical examination

          -  All results from blood chemistry, hematology, and urinalysis should be within normal
             ranges or without clinically significant deviations as per Principal Investigator's
             judgment

          -  Hematology complete blood count [CBC]: hematocrit and hemoglobin must be above the
             lower limit; upper limit may range up to 15 percent (%)

          -  Liver Function Test range as defined in the protocol

          -  Electrocardiogram (12 leads) without clinically significant pathological signs

          -  All women of childbearing potential must have negative tests for pregnancy at
             screening, and at day -1 for each treatment period and at end of trial (EOT)

          -  Vital signs (blood pressure and pulse) in supine position within normal ranges or with
             clinically significant abnormalities as per the Principal Investigator's judgment

          -  All women of childbearing potential who are not pregnant or breastfeeding and who are
             using a highly effective contraceptive method for at least one month before and
             following dosing

          -  Negative result for alcohol breath test and urine test for drugs of abuse at screening
             and at each day -1 of the 2 treatment periods

          -  Negative serology tests for human immunodeficiency virus (HIV1 and HIV2 antibodies),
             hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV) and venereal disease research
             laboratory (VDRL) test screening

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants who have received any investigational drug within 21 days prior to the
             study start

          -  Participants who have donated or lost 450 milliliter (mL) or more of blood within 21
             days prior to the study start

          -  Participants with history of cardiovascular, renal, liver, metabolic,
             gastrointestinal, neurological, endocrine, or hematopoietic (any type of anemia)
             diseases; mental disease, surgery or other organic abnormalities which might affect
             the study of the investigational drug pharmacokinetics

          -  History of gastrointestinal tract surgery

          -  Participants with history of hypersensitivity to the study drug and/or any
             formulation's ingredient; history of drug induced anaphylaxis

          -  Participants who take any other drug 30 days before the study drug dose and for which
             at least seven elimination half-lives had not elapsed

          -  Renal failure or renal impairment assessed by using the Cockcroft-Gault formula

          -  Participant's disagreement or lack of capacity to communicate and cooperate with the
             Investigator, lack of legal capacity or limited legal capacity which prevent him/her
             from continuing in the study

          -  Refusal of the high-fat diet which is necessary to assess the food effect.
             Considerable deviations to the diet's normal nutritional patterns

          -  Participants who have smoked tobacco, having drunk alcohol, or xanthines containing
             beverages or food above 600 mg of caffeine a day those who have had grilled food
             within 24 h prior to the drug dosing

          -  Intake of grapefruit, orange, cranberries or their juices within 14 days prior to the
             drug's dosing and throughout the study

          -  Legal inability or limited legal capacity

          -  Incarcerated participants

          -  Participants who have been exposed to agents known as liver enzyme systems' inducers
             or inhibitors, or who have taken potentially toxic drugs within 30 days prior to the
             study

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CECYPE</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Food effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

